Table 2.
Prevalence, Persistence, and Incidence of Type-Specific Anal Human Papillomavirus Infection Among Men Who Have Sex With Men and Men Who Have Sex With Women in the HPV in Men (HIM) Study, 2005–2009
MSM (n = 156) |
MSW (n = 954) |
||||||||||||
Incident anal infections |
Incident anal infections |
||||||||||||
HPV type | Period prevalence, No. (%)a | Persistent infection, No. (%)b | Men at risk, No. c | Men with infection, No. | Person-months | Incidence rate (95% CI) d | Period prevalence, No. (%)a | Persistent infection, No. (%)b | Men at risk, No. c | Men with infection, No. | Person-months | Incidence rate (95% CI)d | IRR (95% CI) |
Any HPV | 97 (62.2) | 50 (32.1) | 72 | 13 | 502 | 25.9 (13.8–44.3) | 174 (18.2) | 40 (4.2) | 829 | 49 | 6032 | 8.1 (6.0–10.7) | 3.2 (1.7–5.9) |
Oncogenic | 65 (41.7) | 25 (16.0) | 107 | 16 | 756 | 21.2 (12.1–34.3) | 86 (9.0) | 15 (1.6) | 892 | 24 | 6472 | 3.7 (2.4–5.5) | 5.7 (3.0–10.7) |
16 | 16 (10.3) | 8 (5.1) | 145 | 5 | 1038 | 4.8 (1.6–11.2) | 26 (2.7) | 0 (0.0) | 933 | 5 | 6782 | 0.7 (.2–1.7) | 6.5 (1.9–22.6) |
18 | 12 (7.7) | 3 (1.9) | 148 | 4 | 1060 | 3.8 (1.0–9.7) | 8 (0.8) | 0 (0.0) | 952 | 6 | 6916 | 0.9 (.3–1.9) | 4.3 (1.2–15.4) |
31 | 4 (2.6) | 0 (0.0) | 153 | 1 | 1095 | 0.9 (.0–5.1) | 4 (0.4) | 2 (0.2) | 951 | 1 | 6909 | 0.1 (.0–.8) | 6.3 (.4–100.8) |
33 | 6 (3.9) | 1 (0.6) | 152 | 2 | 1088 | 1.8 (.2–6.6) | 3 (0.3) | 0 (0.0) | 952 | 1 | 6908 | 0.1 (.0–.8) | 12.7 (1.2–140.0) |
35 | 7 (4.5) | 3 (1.9) | 150 | 1 | 1067 | 0.9 (.0–5.2) | 1 (0.2) | 0 (0.0) | 953 | 0 | 6922 | 0.0 - | … |
39 | 9 (5.8) | 3 (1.9) | 148 | 1 | 1062 | 0.9 (.0–5.2) | 8 (0.8) | 1 (0.1) | 951 | 5 | 6908 | 0.7 (.2–1.7) | 1.3 (.2–11.1) |
45 | 8 (5.1) | 2 (1.3) | 151 | 3 | 1076 | 2.8 (.6–8.1) | 5 (0.5) | 2 (0.2) | 950 | 1 | 6904 | 0.1 (.0–.8) | 19.2 (2.0–185.0) |
51 | 13 (8.3) | 4 (2.6) | 146 | 3 | 1048 | 2.9 (.6–8.4) | 19 (2.0) | 4 (0.4) | 942 | 7 | 6834 | 1.0 (.4–2.1) | 2.8 (.7–10.8) |
52 | 13 (8.3) | 4 (2.6) | 150 | 7 | 1075 | 6.5 (2.6–13.4) | 6 (0.6) | 2 (0.2) | 951 | 3 | 6909 | 0.4 (.1–1.3) | 15.0 (3.9–58.0) |
56 | 6 (3.9) | 1 (0.6) | 151 | 1 | 1077 | 0.9 (.0–5.2) | 6 (0.6) | 1 (0.1) | 949 | 1 | 6881 | 0.1 (.0–.8) | 6.4 (.4–102.1) |
58 | 7 (4.5) | 2 (1.3) | 152 | 3 | 1089 | 2.8 (.6–8.1) | 7 (0.7) | 1 (0.1) | 950 | 3 | 6904 | 0.4 (.1–1.3) | 6.3 (1.3–31.4) |
59 | 11 (7.1) | 1 (0.6) | 151 | 6 | 1065 | 5.6 (2.1–12.3) | 9 (0.9) | 0 (0.0) | 946 | 1 | 6877 | 0.1 (.0–.8) | 38.7 (4.7–321.8) |
68 | 5 (3.2) | 2 (1.3) | 154 | 3 | 1101 | 2.7 (.6–8.0) | 4 (0.4) | 3 (0.3) | 951 | 1 | 6910 | 0.1 (.0–.8) | 18.8 (2.0–181.0) |
Non-oncogenic | 85 (54.5) | 39 (25.0) | 86 | 15 | 615 | 24.4 (13.7–40.2) | 119 (12.5) | 29 (3.0) | 875 | 40 | 6360 | 6.3 (4.5–8.6) | 3.9 (2.1–7.0) |
06 | 18 (11.5) | 8 (5.1) | 141 | 3 | 1012 | 3.0 (.6–8.7) | 25 (2.6) | 4 (0.4) | 935 | 6 | 6800 | 0.9 (.3–1.9) | 3.4 (.8–13.4) |
11 | 7 (4.5) | 3 (1.9) | 151 | 2 | 1079 | 1.9 (.2–6.7) | 2 (0.2) | 0 (0.0) | 953 | 1 | 6922 | 0.1 (.0–.8) | 12.8 (1.2–141.6) |
26 | 1 (0.6) | 0 (0.0) | 155 | 0 | 1109 | 0.0 - | 0 (0.0) | 0 (0.0) | 954 | 0 | 6929 | 0.0 - | … |
40 | 3 (1.9) | 0 (0.0) | 153 | 0 | 1095 | 0.0 - | 0 (0.0) | 0 (0.0) | 954 | 0 | 6929 | 0.0 - | … |
42 | 5 (3.2) | 0 (0.0) | 155 | 4 | 1109 | 3.6 (1.0–9.2) | 3 (0.3) | 1 (0.1) | 952 | 1 | 6906 | 0.1 (.0–.8) | 24.9 (2.8–222.9) |
53 | 18 (11.5) | 5 (3.2) | 143 | 5 | 1018 | 4.9 (1.6–11.5) | 13 (1.4) | 3 (0.3) | 946 | 5 | 6865 | 0.7 (.2–1.7) | 6.7 (2.0–23.3) |
54 | 8 (5.1) | 2 (1.3) | 150 | 2 | 1075 | 1.9 (.2–6.7) | 7 (0.7) | 2 (0.2) | 951 | 4 | 6908 | 0.6 (.2–1.5) | 3.2 (.6–17.5) |
55e | 5 (3.2) | 2 (1.3) | 153 | 2 | 1092 | 1.8 (.2–6.6) | 3 (0.3) | 1 (0.1) | 953 | 2 | 6923 | 0.3 (.0–1.0) | 6.3 (.9–45.0) |
61 | 11 (7.1) | 6 (3.9) | 147 | 2 | 1051 | 1.9 (.2–6.9) | 15 (1.6) | 5 (0.5) | 944 | 5 | 6957 | 0.7 (.2–1.7) | 2.6 (.5–13.5) |
62 | 8 (5.1) | 2 (1.3) | 151 | 3 | 1081 | 2.8 (.6–8.1) | 22 (2.3) | 6 (0.6) | 940 | 8 | 6825 | 1.2 (.5–2.3) | 2.4 (.6–8.9) |
64e | 1 (0.6) | 0 (0.0) | 156 | 1 | 1115 | 0.9 (.0–5.0) | 0 (0.0) | 0 (0.0) | 954 | 0 | 6929 | 0.0 - | … |
66 | 5 (3.2) | 1 (1.3) | 152 | 1 | 1083 | 0.9 (.0–5.1) | 9 (0.9) | 2 (0.2) | 948 | 3 | 6881 | 0.4 (.1–1.3) | 2.1 (.2–20.4) |
67 | 3 (1.9) | 0 (0.0) | 154 | 1 | 1101 | 0.9 (.0–5.1) | 1 (0.1) | 0 (0.0) | 953 | 0 | 6921 | 0.0 - | … |
69 | 2 (1.3) | 0 (0.0) | 154 | 0 | 1102 | 0.0 - | 0 (0.0) | 0 (0.0) | 954 | 0 | 6929 | 0.0 - | … |
70 | 14 (9.0) | 3 (1.9) | 148 | 6 | 1060 | 5.7 (2.1–12.3) | 4 (0.4) | 0 (0.0) | 952 | 2 | 6917 | 0.3 (.0–1.0) | 19.6 (4.0–97.0) |
71 | 8 (5.1) | 4 (2.6) | 150 | 2 | 1073 | 1.9 (.2–6.7) | 5 (0.5) | 2 (0.2) | 949 | 0 | 6896 | 0.0 - | … |
72 | 7 (4.5) | 0 (0.0) | 155 | 6 | 1108 | 5.4 (2.0–11.8) | 4 (0.4) | 0 (0.0) | 951 | 1 | 6910 | 0.1 (.0–.8) | 37.4 (4.5–310.6) |
73 | 16 (10.3) | 5 (3.2) | 146 | 6 | 1042 | 5.8 (2.1–12.5) | 2 (0.2) | 0 (0.0) | 952 | 0 | 6915 | 0.0 - | … |
81 | 9 (5.8) | 4 (2.6) | 150 | 3 | 1068 | 2.8 (.6–8.2) | 6 (0.6) | 3 (0.3) | 949 | 1 | 6884 | 0.1 (.0–.8) | 19.3 (2.0–185.8) |
82 | 5 (3.2) | 1 (0.6) | 152 | 1 | 1087 | 0.9 (.0–5.1) | 1 (0.1) | 0 (0.0) | 954 | 1 | 6929 | 0.1 (.0–.8) | 6.4 (.4–101.9) |
83 | 7 (4.5) | 0 (0.0) | 151 | 2 | 1065 | 1.9 (.2–6.8) | 5 (0.5) | 0 (0.0) | 950 | 1 | 6902 | 0.1 (.0–.8) | 13.0 (1.2–143.0) |
84 | 22 (14.1) | 6 (3.9) | 140 | 6 | 1000 | 6.0 (2.2–13.1) | 14 (1.5) | 1 (0.1) | 947 | 7 | 6881 | 1.0 (.4–2.1) | 5.9 (2.0–17.6) |
89e | 17 (10.9) | 3 (1.9) | 148 | 9 | 1057 | 8.5 (3.9–16.2) | 14 (1.5) | 3 (0.3) | 943 | 3 | 6848 | 0.4 (.1–1.3) | 19.4 (5.3–71.8) |
IS39e | 3 (1.9) | 1 (0.6) | 154 | 1 | 1102 | 0.9 (.0–5.1) | 0 (0.0) | 0 (0.0) | 954 | 0 | 6929 | 0.0 - | … |
Abbreviations: CI, confidence interval; HPV, human papillomavirus; IRR, incidence rate ratio; MSM, men who have sex with men; MSW, men who have sex with women.
The number and proportion of men with type-specific infection at either enrollment or the 6-month visit.
The number and proportion of men with type-specific infection at both enrollment and the 6-month visit.
The number of men negative for a specific type at enrollment.
The number of infections per 1000 person-months.
HPV-55 is considered a subtype of HPV-44; HPV-64 is considered a subtype of HPV-34; IS39 is considered a subtype of HPV-82; HPV-89, previously CP6108.